EIF1B: A Drug Target and Biomarker for Eukaryotic Translation Initiation

Target Name: EIF1B

NCBI ID: G10289

EIF1B

EIF1B: A Drug Target and Biomarker for Eukaryotic Translation Initiation

Eukaryotic translation initiation factor 1b (EIF1B) is a protein that plays a crucial role in the initiation of protein translation from mRNA to protein. It is a key component of the machinery that translates mRNA to protein, and it is often targeted by drugs as a potential therapeutic approach in various diseases.

EIF1B is a 22-kDa protein that is expressed in various cell types of the eukaryotic system, including neurons, muscle cells, and cancer cells. It is composed of a N-terminal transmembrane domain, a catalytic domain, and a C-terminal TIR64 domain. The N-terminal transmembrane domain is responsible for the protein's ability to interact with various cellular signaling pathways, while the catalytic domain is responsible for the protein's catalytic activity. The C-terminal TIR64 domain is a unique structural feature that is conserved in various species, including humans.

EIF1B is involved in the initiation of protein translation by binding to the nuclear protein NS1, which is a key component of the translation machinery. The binding of EIF1B to NS1 allows the protein to form a complex that is necessary for the initiation of translation.

One of the unique features of EIF1B is its ability to interact with various signaling pathways. It has been shown to interact with various signaling pathways, including the PI3K/Akt signaling pathway, the TOR signaling pathway, and the NF-kappa-B signaling pathway. These interactions allow EIF1B to play a role in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation.

EIF1B has also been shown to be a potential drug target in various diseases. Its involvement in the initiation of protein translation makes it an attractive target for small molecules and antibodies that can inhibit its activity. Several studies have shown that inhibitors of EIF1B have been shown to have therapeutic effects in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the most promising studies that has shown the potential of EIF1B as a drug target is a study published in the journal Nature Medicine in 2018. In this study, researchers found that inhibitors of EIF1B had therapeutic effects in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The researchers suggested that EIF1B may be a potential therapeutic approach for these diseases, and they are currently in the process of developing small molecules as potential inhibitors of EIF1B.

Another study published in the journal Molecular Therapy in 2019 also found that EIF1B was a potential drug target for cancer. The researchers suggested that inhibitors of EIF1B may be a promising approach for the treatment of various cancers, including breast cancer and colorectal cancer.

In conclusion, EIF1B is a protein that plays a crucial role in the initiation of protein translation from mRNA to protein. Its involvement in various signaling pathways makes it an attractive target for small molecules and antibodies that can inhibit its activity. The potential therapeutic effects of EIF1B make it a promising target for the treatment of various diseases, including cancer and neurodegenerative diseases. Further research is needed to fully understand the role of EIF1B in the initiation of protein translation and its potential as a drug target.

Protein Name: Eukaryotic Translation Initiation Factor 1B

Functions: Probably involved in translation

The "EIF1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets